According to reports, small compounds such as EZH2 inhibitors that disrupt epigenetic regulation or IDO1 inhibitors that modulate metabolic pathways have boosted the anti-tumor immunity induced by PD-1/PD-L1 inhibitors. This evidence concerns the gene PDCD1 and neoplasm.